OncoCyte Corporation (OCX)

OncoCyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-40.15	-28.72	-73.42	-64.1	-29.93	-22.43
Depreciation & Amortization	1.54	1.68	5.22	4.21	0.39	0.35
Share-Based Compensation	2.52	2.89	10.04	6.84	5.07	3
Other Operating Activities	18.61	-0.11	12.07	17.11	-1.51	-0.64
Operating Cash Flow	-17.48	-23.33	-45.57	-35.94	-25.98	-19.72
Capital Expenditures	0.05	0.07	-4.34	-2.25	-1.23	-0.92
Acquisitions	-1.37	-1.37	0	-11.71	-10.51	-11.25
Change in Investments	0.37	0.37	0	0	0	0
Other Investing Activities	-	-	-	-	-0.01	-0.25
Investing Cash Flow	-0.96	-0.93	-4.34	-13.96	-11.75	-12.42
Share Issuance / Repurchase	13.85	13.85	32.84	82.96	22.24	49.79
Debt Issued / Paid	-0.09	-0.12	-1.43	-1.53	0.7	1.36
Other Financing Activities	-1.55	-1.55	4.39	-3.07	-0.13	-3.29
Financing Cash Flow	12.21	12.19	35.81	78.36	22.8	47.87
Net Cash Flow	-6.23	-12.07	-14.1	28.46	-14.93	15.74
Free Cash Flow	-17.43	-23.25	-49.91	-38.19	-27.21	-20.63
Free Cash Flow Margin	-1261.51%	-1547.04%	-5209.60%	-1737.40%	-2237.42%	-
Free Cash Flow Per Share	-2.11	-3.04	-9.01	-8.59	-8.31	-8.04

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).